<DOC>
	<DOCNO>NCT02707562</DOCNO>
	<brief_summary>32 cystic fibrosis patient G551D mutation treat 4 week , consist three consecutive treatment period : two 1-week period follow one 2-week period , evaluate one dose GLPG1837 . After treatment period , 7-10 day follow-up period . During course study , subject examine side effect may occur ( safety tolerability ) . Changes sweat chloride assess biomarker baseline onwards , change pulmonary function ( efficacy ) explore throughout study . The amount GLPG1837 present blood ( pharmacokinetics ) also determine .</brief_summary>
	<brief_title>Study GLPG1837 Subjects With Cystic Fibrosis ( G551D Mutation )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female subject ≥ 18 year age , confirm diagnosis cystic fibrosis Subjects gate G551D CFTR mutation least one allele CFTR gene Subjects currently receive treatment ivacaftor stable regimen treatment regimen ivacaftor , least 2 week prior screen Weight ≥ 40.0 kg Subjects stable concomitant treatment regimen least 4 week prior baseline ( exclude ivacaftor ) Pre postbronchodilator FEV1 ≥ 40 % predict normal Subject use highly effective contraceptive method On ivacaftorcontaining treatment regimen unable unwilling discontinue ivacaftor washout treatment period study Concomitant use antifungal drug within 4 week baseline A history clinically meaningful unstable uncontrolled chronic disease Liver cirrhosis portal hypertension Any significant change medical regimen pulmonary health within 4 week baseline Unstable pulmonary status respiratory tract infection change therapy pulmonary disease within 4 week baseline Abnormal liver function Clinically significant abnormality ECG History malignancy , solid organ/haematological transplantation Abnormal renal function Participation another experimental therapy study within 30 day 5 time halflife</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cystic fibrosis G551D mutation</keyword>
	<keyword>GLPG1837</keyword>
</DOC>